Amyotrophic lateral sclerosis (ALS) is a relentless and devastating motor system degenerative disease, leading to death from respiratory failure typically within 3-5 years from first symptoms. Up to 15% of ALS is familial, with a Mendelian pattern of inheritance, while the remaining is a complex association between genetic susceptibility and environmental exposure. [1] [2] [3] There is evolving evidence of population-based differences in genetic susceptibility, rendering the identification of robust associations among individual susceptibility genes and clinical disease symptoms challenging. However, the identification of such associations promises not only to help in understanding of the disease, but also may lead to improved population stratification for clinical trial enrollment.
Ataxin-2 expands insight into the ALS clinical spectrum
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So far, around 20 genes have been convincingly associated with ALS, including the presence of intermediate polyQ repeat expansions in ATXN2.
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ATXN2 is one of the polyQ disease genes in which expansions of ;Q35 and higher are associated with spinocerebellar ataxia type 2. [4] [5] [6] Whereas the normal ATXN2 repeat length is Q22/Q23, intermediate polyQ expansions of .Q27 have shown significant association with ALS. 7 This association of intermediate length polyQ repeat expansions in ATXN2 with ALS has been confirmed in a broad range of populations and ethnic groups, with a repeat threshold of $Q31. 8 In this issue of Neurology ® , Chiò et al. 8 show that expansions in ATXN2 are also associated with a characteristic clinical phenotype: ATXN2 repeat expansions of .Q31 are associated with spinal onset disease and shorter survival. The study represents a model of good design, as it included a study cohort as well as a replication cohort, each comprising over 650 well-phenotyped patients, with appropriate population-and region-based controls. The findings convincingly suggest that polyQ repeats in ATXN2 modulate clinical disease presentation in this sample. The work also complements other recent studies that suggest an interaction between ATXN2 and other known ALS-associated genes in the determination of clinical phenotype. For example, the presence of ATXN2 expansions increases the likelihood of ALS in those with C9ORF72 hexanucleotide expansion and frontotemporal dementia. 9 Moreover, patients with the C9ORF72 repeat expansion show greater spinal cord motor neuron pathology of TDP-43 with PolyA binding protein, 10 a factor implicated in ATXN2 toxicity 11 and highlighting a stress granule association with disease. 12 These findings are an important step toward integrating genetic associations of ALS disease with clinical heterogeneity.
There is evolving clinical evidence that some forms of ALS are oligogenic, and that disease may occur because 2 or more at-risk genes interact at a cell biological level. 13 Further underscoring this, simple yeast and fly model organisms identified a striking genetic interaction between ATXN2 and TDP-43. 7 Indeed, the strong genetic interaction between TDP-43 and ATXN2 in model organisms led to the original hypothesis that polyQ repeat expansions may also be relevant to ALS pathogenesis. Drosophila shows a stronger interaction on TDP-43-associated lifespan between ATXN2 with repeat expansions in the ALS range (Q32) compared to normal (Q22).
11 Intriguingly, Chiò et al. found evidence of a possible dosesensitive repeat-length effect of ATXN2 expansions on patient survival, with repeat expansions of Q27-Q30 being intermediate in prognosis compared to those of normal and of .Q31, which display poorest prognosis. In Drosophila, the interaction between ATXN2 and TDP-43 in the nervous system is markedly dose-sensitive: lowering the endogenous fly ATXN2 levels by ;50% (which has no consequence in the wild type background) restores the severely curtailed lifespan of TDP-43-expressing animals to near normal. 7 These findings on the influence of normal gene activity in model organisms, together with the demonstrable effect of intermediate repeat expansions in ATXN2 in some ALS cases, argues for ATXN2 as an appealing therapeutic target. 14, 15 The studies by Chiò et al. have effectively translated existing knowledge regarding the biology of ATXN2 into a clinical setting. The work on ATXN2 as a whole also underscores how simple systems, in which functional data can be discovered and tested, can provide important insights into many complex aspects of human disease. Undoubtedly, other genetic modifiers of clinical phenotype await discovery. Model organisms can provide clues at the level of gene and protein interaction, and Chiò et al. have shown how effective translation can be achieved using large and carefully characterized populations. Ultimately, this work demonstrates how it is possible to substratify patients with ALS based on a combination of excellent phenotyping linked to detailed genotyping. As we unravel the complex nature of ALS, it is to be expected that future clinical trials will seek to stratify patients according to particular clinical and genetic characteristics. This approach heralds an era of personalized medicine, in which efficacious drugs are tailored to appropriately characterized patient populations, thus enhancing the prospect of therapeutic success.
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